Yu Guanhua, Wei Ran, Li Shuofeng, Wang Yongjiao, Liu Hengchang, Chen Tianli, Guan Xu, Wang Xishan, Jiang Zheng
Department of Colorectal Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Community Health Service Center, Zaoyuan Sub-District Office, Jinan, China.
Front Oncol. 2022 Sep 29;12:957608. doi: 10.3389/fonc.2022.957608. eCollection 2022.
Radiation therapy (RT) is a standard treatment for the local control of primary pelvic cancers (PPC), yet the risk of second corpus uteri cancer (SCUC) in PPC patients undergoing RT is still controversial. This study investigated the impact of RT on the risk of SCUC and assessed the survival outcome.
We queried nine cancer registries for PPC cases in the Surveillance, Epidemiology, and End Results (SEER) database. The cumulative incidence of SCUC was analyzed using Cox regression and Fine-Gray competing risk regression analysis. The Poisson regression analysis was employed to assess the standardized incidence ratios (SIRs) and radiation-attributed risk (RR) for SCUC. We evaluated the overall survival of patients with SCUC using the Kaplan-Meier method.
Receiving radiotherapy was strongly associated with a higher risk of developing SCUC for PPC patients in Fine-Gray competing risk regression (No-RT vs. RT: adjusted HR = 1.77; 95% CI, 1.40-2.28; < 0.001). The incidence of SCUC in PPC patients who received RT was higher than in the US general population (SIR, 1.66; 95% CI, 1.41-1.93; < 0.05), but the incidence of SCUC in patients who did not receive RT was lower than with the US general population (SIR, 0.68; 95% CI, 0.61-0.75; < 0.05). The dynamic SIR and RR for SCUC decreased with decreasing age at PPC diagnosis and decreased with time progress. In terms of overall survival, 10-year survival rates with SCUC after No-RT (NRT) and SCUC after RT were 45.9% and 25.9% (HR = 1.82; 95% CI, 1.46-2.29; < 0.001), respectively.
Radiotherapy for primary pelvic cancers is associated with a higher risk of developing SCUC than patients unexposed to radiotherapy. We suggest that patients with pelvic RT, especially young patients, should receive long-term monitoring for the risk of developing SCUC.
放射治疗(RT)是原发性盆腔癌(PPC)局部控制的标准治疗方法,但接受RT的PPC患者发生子宫体第二原发癌(SCUC)的风险仍存在争议。本研究调查了RT对SCUC风险的影响,并评估了生存结局。
我们在监测、流行病学和最终结果(SEER)数据库中查询了九个癌症登记处的PPC病例。使用Cox回归和Fine-Gray竞争风险回归分析来分析SCUC的累积发病率。采用泊松回归分析来评估SCUC的标准化发病率比(SIR)和放射归因风险(RR)。我们使用Kaplan-Meier方法评估SCUC患者的总生存期。
在Fine-Gray竞争风险回归中,接受放疗与PPC患者发生SCUC的较高风险密切相关(未放疗组与放疗组:调整后HR = 1.77;95%CI,1.40 - 2.28;P < 0.001)。接受RT的PPC患者中SCUC的发病率高于美国一般人群(SIR,1.66;95%CI,1.41 - 1.93;P < 0.05),但未接受RT的患者中SCUC的发病率低于美国一般人群(SIR,0.68;95%CI,0.61 - 0.75;P < 0.05)。SCUC的动态SIR和RR随着PPC诊断时年龄的降低而降低,并随着时间的推移而降低。就总生存期而言,未放疗(NRT)后发生SCUC和放疗后发生SCUC的10年生存率分别为45.9%和25.9%(HR = 1.82;95%CI,1.46 - 2.29;P < 0.001)。
与未接受放疗的患者相比,原发性盆腔癌的放射治疗与发生SCUC的较高风险相关。我们建议接受盆腔放疗的患者,尤其是年轻患者,应接受长期监测以防发生SCUC的风险。